VAR2 PHARMACEUTICALS ApS: Financial statements 2016
CVR: 34621942
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
VAR2 PHARMACEUTICALS ApS (CVR 34621942) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK -1,632,539 and a net result of DKK -1,856,736 compared with DKK -769,829 the year before. Equity in the 2016 report amounted to DKK 9,855,332. The solvency ratio was 96.9%.
- Gross Profit
- DKK -1,632,539
- Profit/Loss
- DKK -1,856,736
- Equity
- DKK 9,855,332
- Total Assets
- DKK 10,171,879
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | -1.6 mio. | -1.9 mio. | 9.9 mio. | - |
| 2015 | - | -654 t. | -770 t. | 3.5 mio. | - |
| 2014 | - | -829 t. | -1 mio. | 906 t. | - |
| 2013 | - | 68 t. | 66 t. | 118 t. | - |
Official annual report
Find more companies like VAR2 PHARMACEUTICALS ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
VAR2 PHARMACEUTICALS ApS has published its annual report for 2015. Gross profit came to DKK -654,287, and the net result was DKK -769,829.
As of May 14, 2016, Mai-Britt Zocca has joined the board of directors of VAR2 PHARMACEUTICALS ApS.
As of May 14, 2016, Thor Grundtvig Theander has joined the board of directors of VAR2 PHARMACEUTICALS ApS.
As of May 14, 2016, Ali El-Salanti has joined the board of directors of VAR2 PHARMACEUTICALS ApS.
As of May 14, 2016, Mads Daugaard has joined the board of directors of VAR2 PHARMACEUTICALS ApS.
As of May 14, 2016, Peter Schröcksnadel has joined the board of directors of VAR2 PHARMACEUTICALS ApS.
As of May 14, 2016, Poul Henrik Bredahl Sørensen has joined the board of directors of VAR2 PHARMACEUTICALS ApS.
About VAR2 PHARMACEUTICALS ApS
VAR2 PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ali El-Salanti and Mads Daugaard. The board consists of Mads Daugaard (chair), Ali El-Salanti, Josef Rainer and Peter Schröcksnadel. The company is owned by ONCOMAL ApS and Københavns Universitet. The company has 11 employees (2018). In 2025, the company reported a gross profit of DKK -21,739,014 and a net result of DKK -19,726,508 compared with DKK -21,006,013 the year before. Equity in the 2025 report amounted to DKK 82,032,248.